Arthemeter-lumefantrine (ART-LUM) is an antimalaria drug manufactured as fixed combination tablets, each containing 20 mg of artemether and 120 mg of lumefantrine. ART-LUM was administrated according to body weight as six consecutive doses: The first dose at diagnosis and the second dose eight hours later, 0- 24-48 hours

Artesunate mefloquine (ASMQ) is an antimalaria drug administered as a combination of artesunate, 4 mg/kg/day, with mefloquine, 8 mg/kg/day orally once a day for 3 days or three times, at an interval of 24 hours (0 h - 24 h - 48 h).

Dihydroartemisinin piperaquine (DHA-PQ ) is an antimalaria drug administered as a combination of dihydroartemisinin, 2.5 mg per kg, with piperaquine phosphate, 20mg per kg daily for 3 days or three times, at an interval of 24 hours

Oral paracetamol is administered at of 50mg/kg body weight per day in three divided doses for fever exceeding 37.5oC.

amoxicillin is an antibiotic administered at 50mg per kg body weight per day for seven days in the event of concomitant bacterial infection, absent on day 0 but present during the follow up.

Quinine is an antimalarial recommended by the WHO and NMCP to be used as second line treatment for malaria. In this study, for cases of treatment failure with the artemisinin based combination therapies, quinine sulphate is administered as a second line or rescue drug at a dose of 25mg base per kg body weight per day in three divided doses for five days. The participant is then classified as ETF or LTF and excluded from the study.

Drug Resistant Malaria Due to Plasmodium Falciparum

Randomization codes were computer-generated by an offsite investigator and provided to a study nurse responsible for treatment allocation. All other study personnel were blinded to the treatment assignments, and patients were not informed of their treatment regimen. Participants from Group 1: AL, Group 2 : DHAP, Group3 : ASMQ were also given appointment card for days 1, 2, 3, 7, 14, 21, 28, 35 and 42 for clinical examination and blood smears. Blood was taken on filter paper on each of these visits.

Arthemeter-lumefantrine

Artequin® is an antimalarial drug presented as infant co-formulation of two separate drugs

Artesunate mefloquine

Malacur®. is an antimalarial drug presentad as co-formulation of two separate drugs

Dihydroartemisinin piperaquine

Paracetamol, is an antipyretic drug, presented as tablets or syrup in infants formulation

Paracetamol

Amoxicillin is an antibiotic with no reported activity on plasmodium

Amoxicillin

quinine sulphate is an antimalaria drug administered as a second line or rescue drug

Quinine

CDC Hospital

Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

The primary endpoint was the 28-day and 42-day cure rates and was defined as proportion of patients with adequate clinical and parasitological response (ACPR) after 28 and 42 days of follow-up. Absence of parasitemia until day 28 and day 42 irrespective of axillary temperature was categorized as an adequate clinical and parasitologic response (ACPR). Secondary endpoints were early treatment failure (ETF), late clinical failure (LCF), late parasitological failure (LPF), adverse events (clinical and laboratory abnormalities), anaemia (Hematocrit < 30%), clearance rate of fever and parasitaemia, and gametocyte

The ability of the drug to restore hemoglobin level back to normal

The ability of the drug to completely eliminate plasmodium in the blood stream including participant without symptoms of fever

blood sample from patients with parasitaemia at any day of follow-up are analysed by PCR to evaluated the genetic profile of the MSP1 and MSP2

University of Bamenda

Ministry of Science and Technology of the People´s Republic of China

National Institute for Parasitic Disease, Chinese Center for Disease Control and Prevention

Serologically Active Adult Systemic Lupus Erythematosus

Autologous EBV specific CTL infusion

CHU de Nantes - Dermatologie

CHU de Nantes - Médecine interne

Hopital La pitié Salpétriere

Autologous EBV-specific Cytotoxic T Cells for the Treatment of Systemic Lupus Erythematosus (SLE)

Restauration of EBV Control in SLE Phase 1-2 Trial Evaluating Adoptive Transfer of Autologous EBV- Specific Cytotoxic T Lymphocytes in SLE Treatment

Tolerance will be assessed by clinical and laboratory examinations to each Visit according to CTC toxicity criteria.

Composite Response of SLE Index (Systemic Lupus Erythematosus Responder Index: Systemic Lupus Erythematosus Disease Activity Index + British Isles Lupus Assessment Group + Physician Global Assessment)

biological parameter measurement biomarkers C3

biological parameter measurement biomarkers C4

biological parameter measurement biomarkers anti-dsDNA antibodies

Nantes University Hospital

Chloroquine diphosphate 250mg/day associated to prednisone in variable doses

azathioprine in variable doses (50-150mg/day) associated to prednisone in variable doses

Chloroquine diphosphate 250mg/day associated to prednisone in variable doses
Chloroquine diphosphate: One pill of chloroquine diphosphate per day until the end of the study
prednisone: Prednisone 5-15 mg/day until the end of the study

Chloroquine Plus Prednisone

azathioprine in variable doses (50-150mg/day) associated to prednisone in variable doses
prednisone: Prednisone 5-15 mg/day until the end of the study
azathioprine: azathioprine 1-2mg/Kg/day until the end of the study

Azathioprine Plus Prednisone

Total

Gender

The biochemical response is defined when there is normalization of hepatic enzymes, mainly AST and ALT.

azathioprine in variable doses (1-2mg/Kg/day) associated to prednisone in variable doses
prednisone: Prednisone 5-15 mg/day until the end of the study
azathioprine: azathioprine 1-2mg/Kg/day until the end of the study

Biochemical Response to Therapy

Histopathological response is achieved when there is minimal or no inflammation in hepatic tissue, as assessed by liver biopsy.

Histopathological Response to Therapy

Overall Study

Lydia Teófilo de Moraes Falcão

Autoimmune Hepatitis

One pill of chloroquine diphosphate per day until the end of the study

Chloroquine diphosphate

Prednisone 5-15 mg/day until the end of the study

prednisone

azathioprine 1-2mg/Kg/day until the end of the study

azathioprine

Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial

Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial

Association of Chloroquine and Prednisone as an Alternative Treatment for Autoimmune Hepatitis: a Randomized Trial

University of Sao Paulo General Hospital

Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)

Ebola Virus Disease

Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.
Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.
Group C: daily dosages will be adapted to their body weight.

Favipiravir

The caregivers treatment center

MSF Ebola treatment centre

French Red Cross Ebola care center

ALIMA Ebola care center

Efficacy of Favipiravir Against Ebola (JIKI)

Efficacy of Favipiravir in Reducing Mortality in Individuals With Ebola Virus Disease in Guinea

Day-0 is the day of the first dose of favipiravir

Composite criteria for cure are the following:
4 days without fever or significant symptoms AND;
able to feed and walk independently AND;
two consecutive negative qualitative PCR.

antimalarial/únava organizmu

Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

Autologous EBV-specific Cytotoxic T Cells for the Treatment of Systemic Lupus Erythematosus (SLE)

Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial

Efficacy of Favipiravir Against Ebola (JIKI)

Najkompletnejšia databáza liečivých bylín podporovaná vedou